Growth Attenuation Therapy: Practice & Perspectives of Pediatric Endocrinologists

Allison J Pollock, MD · Norman Fost MD MPH · David B Allen MD · Department of Pediatrics · University of Wisconsin School of Medicine & Public Health

Background

Growth attenuation therapy (GAT) is administration of exogenous sex steroids before puberty to decrease final height by accelerating epiphysis closure. Treatment of a girl with severe cognitive and physical disabilities in 2006 prompted intense debate. There are no reliable data on GAT prescribing practices and attitudes of pediatric endocrinologists.

Objectives

1. Determine diagnoses that prompt consideration of GAT
2. Assess how often pediatric endocrinologists prescribe GAT
3. Assess pediatric endocrinologists’ attitudes about growth attenuation therapy (GAT) in children with severe physical & cognitive disability

Design

Pediatric Endocrine Society (PES) members received questionnaires (n=1100). Consent was implied by participating. Anonymity was assured with de-identified data collection.

Results

284 (26%) of ~1100 PES members (74% academic physicians) completed the survey.

At least 65 children with severe physical & cognitive disability have been treated with GAT to reduce ultimate height

Respondents’ Attitudes about GAT

Disagree | Agree
--- | ---
33% | 67%
13% | 87%
190 | 85%
135 | 75%
44 | 56%
25 | 75%

GAT Medications Prescribed

1. Oral estrogen (80%)
2. Transdermal estrogen (13%)
3. Androgens (27%)

Diagnoses prompting GAT inquiries

Tall stature

80% 45% 99 55%

Severe physical & cognitive disability

45% 55% 130 48%

Passive GAT experience

Have you withheld treatment for precocious puberty in a child with severe physical and cognitive disability to reduce ultimate height?

No | Yes
--- | ---
143 | 52%
130 | 48%

Reasons respondents did NOT prescribe GAT in children with severe physical & cognitive disability

1. Family decided against (63%)
2. Concern about side effects (43%)
3. Legal concerns (13%)
4. Personal conviction or beliefs (10%)
5. Ethics consultation recommendation (7%)

Conclusions

1. Growth attenuation therapy (GAT) has been prescribed by at least 32 respondents to reduce height in at least 65 children with severe physical & cognitive disability.
2. This therapy is no longer rare. At least 62% (n=175) of respondents have had inquiries for GAT, and 27% (n=74) have prescribed GAT.
3. Severe physical and cognitive disability has replaced tall stature as the main indication for GAT inquiries.
4. More data are needed to assess risks and benefits of GAT by evaluating side effects, linear height reduction and improvement in quality of life.

Acknowledgements

Thank you to the University of Wisconsin Department of Pediatrics, the Pediatric Endocrine Society (PES) and Jens Eickhoff, our biostatistician.

Contact information

Allison Pollock MD apollock@uwhealth.org University of Wisconsin - Madison